Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Malignant Neoplasm of Lung: early-phase trial registry

1 of 2 indexed Malignant Neoplasm of Lung trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Malignant Neoplasm of Lung: 2 US clinical trials tracked, 1 recruiting.

Malignant Neoplasm of Lung is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Verastem, running 1 of these trials.

Enrollment posture brief

Registry condition malignant-neoplasm-of-lung

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Malignant Neoplasm of Lu (th…50%
Open-enrollment share among volume-matched conditions near Malignant Neoplasm of Lung

Malignant Neoplasm of Lung lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Malignant Neoplasm of Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Malignant Neoplasm of Lung is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Verastem 1 trials

Named interventions

Most-linked intervention names on Malignant Neoplasm of Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

avutometinib (VS-6766) and adagrasib Drug
1 trials
Adagrasib Drug
1 trials

US sites by state

Facility locations filed on Malignant Neoplasm of Lung trials. A trial with sites in several states counts in each.

North Carolina 2 trials
Minnesota 2 trials
California 2 trials
Wisconsin 1 trials
Virginia 1 trials
Texas 1 trials
New York 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Malignant Neoplasm of Lung page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Malignant Neoplasm of Lung trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Verastem sponsors the most Malignant Neoplasm of Lung trials on record, review their full trial history before evaluating a specific study. See Verastem's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Neoplasm of Lung condition card totals 2 registered trials; most-linked intervention avutometinib (VS-6766) and adagrasib; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.